Last reviewed · How we verify

Encephalitis caused by human herpesvirus 6 infection — Treatment Landscape & Competitive Intelligence

Encephalitis caused by human herpesvirus 6 infection (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Encephalitis caused by human herpesvirus 6 infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Foscavir FOSCARNET Clinigen Hlthcare Pyrophosphate Analog DNA Polymerase Inhibitor 1991-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Clinigen Hlthcare · 1 drug in Encephalitis caused by human herpesvirus 6 infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Encephalitis caused by human herpesvirus 6 infection:

Cite this brief

Drug Landscape (2026). Encephalitis caused by human herpesvirus 6 infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/encephalitis-caused-by-human-herpesvirus-6-infection. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing